1AI.AX
ALGORAE FPO [1AI]
A$0.01
-4.17%
2026-05-29
About ALGORAE FPO [1AI]
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient for the treatment of cardiovascular disease, such as hypertension; and NTCELL, an alginate coated capsule product for the treatment of Parkinson's disease. It is also developing AlgaraeOS in partnership with the University of New South Wales, a drug discovery platform that uses artificial intelligence protocols and big data analytics for drug discovery and development. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.
Key Fundamentals
EPS (TTM)
A$0.00
ROE
-47.4%
Revenue Growth (YoY)
12.7%
Profit Margin
0.0%
Price/Book
11.50
Beta
-0.07
Market Cap
A$23.3M
Avg Volume (10D)
1.0M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
A$0.02
60D Low
A$0.01
Avg Volume
1.6M
Latest Close
A$0.01
Get breakout alerts for 1AI.AX
Sign up for Breakout Scanner to receive daily notifications when 1AI.AX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
ALGORAE FPO [1AI] (1AI.AX) is listed on the Australian Securities Exchange (ASX). Breakout Scanner monitors 1AI.AX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 1AI.AX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.